Emmaus Life Sciences (EMMA) AI Stock Analysis

• Market Cap: $701.88K
• Dividend Yield: N/A
• Average Volume (3M): 112.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 58.72
• Revenue Growth: -41.78%
• EPS Growth: -101.59%
• Country: US
• Employees: 34
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 70,188,260
• 10 Day Avg. Volume: 152,781
• 30 Day Avg. Volume: 112,453
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.01
• Price to Sales (P/S): 0.07
• P/FCF Ratio: -69.38
• Enterprise Value/Market Cap: 44.36
• Enterprise Value/Revenue: 2.50
• Enterprise Value/Gross Profit: 2.68
• Enterprise Value/Ebitda: -100.43
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $0.01 ▲(0.00% Upside)
• Action: Reiterated Date: 04/09/26
• Date: Action: Reiterated 04/09/26

The score is driven primarily by weak financial performance (persistent losses, negative operating cash flow, and deeply negative equity), which outweighs the benefit of strong gross margins and improved TTM cash burn. Technically, the stock trades below major moving averages with muted momentum. Valuation is constrained by negative earnings, while the recent supply agreement is a modest positive but contingent on conditions being met.

Positive Factors

High gross margins

Sustained very high gross margins indicate durable product-level economics and pricing power for the core L-glutamine therapy. Over months this supports ability to cover fixed costs, fund targeted R&D or manufacturing scale, and make margin-based supply deals more financially meaningful.

Negative Factors

Deeply negative equity

Persistently negative equity reflects accumulated losses and a weakened capital base, constraining balance-sheet flexibility. Over coming months this raises refinancing and dilution risk, limits borrowing capacity, and impairs ability to invest in scale or absorb commercial setbacks without external funding.

Emmaus Life Sciences Business Overview & Revenue Model

Company Description

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidat...

Read more

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidat...

How the Company Makes Money

Emmaus generates revenue primarily from sales of its sickle cell disease therapy (its commercial L-glutamine-based product). Revenue is recognized from product sales to customers (e.g., distributors/wholesalers, pharmacies, hospitals, or other cha...

Read more

Emmaus generates revenue primarily from sales of its sickle cell disease therapy (its commercial L-glutamine-based product). Revenue is recognized from product sales to customers (e.g., distributors/wholesalers, pharmacies, hospitals, or other cha...

Emmaus Life Sciences Financial Statement Overview

Breakdown	Dec 2025	Mar 2025	Jun 2024	Dec 2022	Mar 2022
Income Statement
Total Revenue	12.45M	16.65M	29.60M	18.39M	20.61M
Gross Profit	11.60M	15.45M	28.25M	15.80M	17.30M
EBITDA	-310.00K	-910.00K	3.62M	-5.50M	-12.76M
Net Income	-7.49M	-6.45M	-3.73M	-10.63M	-15.95M
Balance Sheet
Total Assets	21.44M	23.60M	35.18M	48.23M	56.73M
Cash, Cash Equivalents and Short-Term Investments	2.13M	1.39M	2.55M	2.02M	2.28M
Total Debt	32.56M	32.96M	32.65M	30.82M	29.91M
Total Liabilities	85.04M	80.08M	82.94M	82.32M	78.18M
Stockholders Equity	-63.61M	-56.48M	-47.76M	-34.09M	-21.45M
Cash Flow
Free Cash Flow	-12.00K	-2.30M	-1.52M	-5.10M	-1.33M
Operating Cash Flow	-11.00K	-2.29M	-1.50M	-5.07M	-1.25M
Investing Cash Flow	2.17M	2.50M	-432.00K	-2.39M	-6.38M
Financing Cash Flow	-1.43M	-1.35M	2.48M	7.23M	7.41M

Emmaus Life Sciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EMMA, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 44.03 is Neutral, neither overbought nor oversold. The STOCH value of 116.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EMMA.

Emmaus Life Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCNI	44 Neutral	$2.05M	―	―	―	178.82%	-4121.10%
DRMA	44 Neutral	$4.87M	-0.28	-203.36%	―	―	90.53%
EMMA	42 Neutral	$701.88K	-0.11	12.66%	―	-41.78%	-101.59%

Emmaus Life Sciences Corporate Events